Management of Crohn's disease relapse during neoadjuvant chemotherapy for bilateral breast cancer: a case report. Issue 9 (26th September 2022)

• Record Type: Journal Article
• Authors: Yamada, Miki; Jinno, Hiromitsu; Maeda, Yuka; Sato, Ayana; Matsumoto, Akiko; Ikeda, Tatsuhiko; Sasajima, Yuko
• Is Part Of: Oxford medical case reports. Volume 2022:Issue 9(2022)
• Publication Date: 2022-09-26
• Subjects: Clinical medicine -- Case studies -- Periodicals; 616.09
• DOI: 10.1093/omcr/omac095
• Languages: English
• ISSNs: 2053-8855

Abstract

ABSTRACT: Diagnosis of breast cancer in a patient with Crohn's disease (CD) is uncommon. However, cytotoxic chemotherapy might help control CD during the treatment period. Here, we report a case of CD relapse during treatment with neoadjuvant chemotherapy (NAC) for bilateral breast cancer. A 39-year-old woman with CD controlled by infliximab and mesalazine was diagnosed with bilateral breast cancer. Infliximab treatment was discontinued temporarily so that the patient could receive NAC. However, her CD symptoms intensified during chemotherapy, and after her symptoms improved after a one-time administration of infliximab, the remainder of NAC was completed with a corticosteroid. Bilateral breast conservation surgery was performed. Histopathological examination revealed partial response of the left breast cancer and no residual cancer in the right breast. Breast irradiation and hormone therapy were added and no signs of recurrence have been observed for 5 years. CD has been well controlled with adalimumab and mesalazine.